VEA
CBAY

Virtus ETF Advisers’s Cymabay Therapeutics CBAY Stock Holding History

Virtus ETF Advisers’s Portfolio CBAY Stock Details CBAY Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q1 		– Sell
-4,278
Closed -$101K – 491
2023
Q4 		$101K Sell
4,278
-7,065
-62% -$126K 0.06% 352
2023
Q3 		$169K Sell
11,343
-1,127
-9% -$14.9K 0.1% 296
2023
Q2 		$137K Buy
+12,470
New +$116K 0.08% 324
2019
Q4 		– Sell
-40,232
Closed -$206K – 518
2019
Q3 		$206K Sell
40,232
-2,241
-5% -$13.6K 0.04% 245
2019
Q2 		$304K Buy
42,473
+11,526
+37% +$131K 0.06% 207
2019
Q1 		$411K Sell
30,947
-3,490
-10% -$37.1K 0.87% 37
2018
Q4 		$271K Sell
34,437
-1,683
-5% -$16K 0.05% 145
2018
Q3 		$400K Sell
36,120
-25,831
-42% -$321K 0.04% 163
2018
Q2 		$831K Sell
61,951
-31,366
-34% -$393K 0.73% 19
2018
Q1 		$1.21M Buy
93,317
+50,832
+120% +$632K 1.05% 19
2017
Q4 		$391K Buy
+42,485
New +$363K 0.49% 59

Other funds holding CBAY

IA
IFP Advisors Tampa, Florida $5.54B AUM 27.43% 1-Year Est. Return

Virtus ETF Advisers's CBAY Position: Q1 2024 in Review

Virtus ETF Advisers sold out of Cymabay Therapeutics (CBAY) in Q1 2024, closing a stake of 4,278 shares — an estimated $101K sold.

Virtus ETF Advisers first reported a position in CBAY in Q4 2017 and held it in 11 quarters. The position peaked at $1.21M in Q1 2018. 1 fund tracked by Wall St. Rank holds CBAY as of Q1 2024.

  • Virtus ETF Advisers reported no remaining Cymabay Therapeutics position as of Q1 2024 after selling out during the quarter.
  • Virtus ETF Advisers sold 4,278 Cymabay Therapeutics shares in Q1 2024, an estimated $101K.
  • Virtus ETF Advisers first reported a position in Cymabay Therapeutics in Q4 2017 and held it in 11 quarters.
  • Virtus ETF Advisers's Cymabay Therapeutics position peaked at $1.21M in Q1 2018.
  • 1 fund tracked by Wall St. Rank held Cymabay Therapeutics as of Q1 2024.

Based on Virtus ETF Advisers's 13F filing for Q1 2024, filed 15 May 2024.